Sepsis & Septic Shock

Sepsis and Septic Shock: 2026 Guidelines, Evidence & Trials

Current standard of care, organized by treatment area, with the trials behind each recommendation — anchored to the new Surviving Sepsis Campaign 2026 guideline.

Reviewed by the DosePilot Medical Team · Last reviewed: Jun 2026 · Independent — no industry funding
How to read this page. Each treatment area opens with the current approach, then the trials behind it (design, key results, limitations), and a short practical note (In practice). Where the Surviving Sepsis Campaign 2026 changed a recommendation, the badge shows the shift (e.g. suggest → recommend). All targets and figures are taken from the cited primary sources (DOI + PMID). In practice notes are general practical guidance, not a substitute for clinical judgment.
How we verify evidence & editorial policy
Written and maintained by the DosePilot Medical Team. Recommendations are based on randomized controlled trials and current society guidelines (GRADE). Every citation is verified directly against PubMed (PMID) and the publisher DOI — no memory-based or AI-generated references. Each topic is peer-reviewed by the clinical team before publication and re-reviewed at least every 12 months or when major new evidence appears.

Funding & conflicts of interest. Produced independently; no industry funding was received for this content and contributors report no relevant financial conflicts of interest.
On this page
  1. Evidence timeline
  2. Definition & diagnosis
  3. Screening & early recognition
  4. Antibiotics & source control
  5. Fluid resuscitation
  6. Vasopressors & hemodynamic targets
  7. Corticosteroids
  8. Respiratory support & adjuncts to avoid
  9. Post-sepsis care & transitions
  10. Where it’s heading
  11. Bottom line
  12. FAQ
  13. Related DosePilot tools
  14. Guidelines & evidence basis
At a glance — current standard of care (SSC 2026)
AreaCurrent approachKey trial(s)
ScreeningNEWS / NEWS2 / MEWS / SIRS over qSOFA; hospital PI programSSC 2026
DiagnosisSepsis-3: organ dysfunction (SOFA ≥2); shock = pressor + lactate >2Sepsis-3
AntibioticsCultures first; ≤1 h if shock or sepsis, decide ≤3 h if possible sepsis; de-escalateSSC 2026
Beta-lactamsProlonged infusion after a loading dose (now strong)BLING-III
Source controlDrain / debride / remove the focus as early as feasible—
AreaCurrent approachKey trial(s)
Fluids~30 mL/kg balanced crystalloid, then restrictive or liberalCLASSIC; CLOVERS
VasopressorNorepinephrine first; MAP ≥65; start early / peripherally65 trial; SEPSISPAM
Add-onsVasopressin, then epinephrine; angiotensin II optionVASST; ATHOS-3
SteroidsHydrocortisone ± fludrocortisone in pressor-dependent shockAPROCCHSS; ADRENAL
RespirationHFNC first; avoid blood purification / probiotics / β-blockersSSC 2026

1Evidence timeline (2001–2026)

2001Rivers — early goal-directed therapy (EGDT) cuts in-hospital mortality 30.5% vs 46.5%; launches protocolized early resuscitation
2008VASST — adding low-dose vasopressin to norepinephrine: no overall mortality benefit
2010SOAP II — norepinephrine over dopamine (fewer arrhythmias; dopamine worse in cardiogenic shock)
2014ProCESS & ARISE — protocolized EGDT no better than usual care; SEPSISPAM — MAP 80–85 vs 65–70 no benefit
2015ProMISe — confirms EGDT ≈ usual care; bundles shift toward early antibiotics + fluids, not protocolized catheters
2016Sepsis-3 — organ-dysfunction definition (SOFA, qSOFA); VANISH (vasopressin vs norepinephrine, renal outcomes)
2017ATHOS-3 — angiotensin II raises MAP in refractory vasodilatory shock (FDA approval)
2018ADRENAL (hydrocortisone, neutral mortality) & APROCCHSS (hydrocortisone + fludrocortisone, mortality benefit); SMART — balanced crystalloid signal in sepsis
202065 trial — permissive MAP 60–65 in patients ≥65 y reduces vasopressor exposure without harm
2021BaSICS — balanced ≈ saline; SSC 2021 guideline (1 h antibiotics, 30 mL/kg, norepinephrine first)
2022PLUS — balanced ≈ saline (n≈5,000); CLASSIC — restrictive ≈ standard fluids in septic shock
2023CLOVERS — restrictive (vasopressor-first) ≈ liberal fluids for sepsis-induced hypotension
2024BLING-III — continuous vs intermittent β-lactams: 90-day mortality 24.9% vs 26.8% (favorable, not significant)
2026SSC 2026 — 129 statements (46 new): β-lactam infusion & de-escalation upgraded to strong; norepinephrine first-line downgraded to suggest; corticosteroids downgraded/broadened; NEWS/NEWS2/MEWS/SIRS over qSOFA

2Definition & diagnosis

Current approach (2026)
Consensus definition (Sepsis-3)
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection — operationally, a suspected/confirmed infection plus an acute rise in SOFA score of ≥2 points. Septic shock is the subset with circulatory and metabolic derangement carrying higher mortality: a vasopressor requirement to keep MAP ≥65 mmHg and a serum lactate >2 mmol/L despite adequate fluid resuscitation. The older SIRS-based “severe sepsis” terminology is retired. Diagnosis is clinical — do not wait for a positive culture.
Evidence — old → new
1992
SIRS era (Sepsis-1/2). Sepsis defined by ≥2 systemic inflammatory response (SIRS) criteria plus infection. Sensitive but non-specific — SIRS is common in non-infected patients — and it missed organ dysfunction.
2016
Sepsis-3 (the current definition). Consensus task force re-grounded sepsis in organ dysfunction. An acute SOFA ≥2 reflects ~10% in-hospital mortality. Introduced qSOFA (respiratory rate ≥22, altered mentation, systolic BP ≤100) as a rapid bedside flag for poor outcome outside the ICU. Septic shock criteria (pressor + lactate >2) identify a group with >40% mortality.

What changed. From “infection + inflammation” (SIRS) to “infection + organ dysfunction” (SOFA). “Severe sepsis” disappeared; lactate became central to defining shock.

Significance. The label now tracks the patients who actually deteriorate, sharpening both trial enrolment and bedside triage — but qSOFA was later found too insensitive to use as a stand-alone screen (see next section).

In practice

Think sepsis whenever infection coincides with new organ dysfunction — rising creatinine, low platelets, altered mentation, hypoxemia, hypotension, or a lactate rise. Confirm shock with a lactate and the need for vasopressors after fluids; don’t let a pending culture delay treatment.

Sources (2)
  • Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI 10.1001/jama.2016.0287. PMID 26903338.
  • Shankar-Hari M, et al. Developing a new definition and assessing new clinical criteria for septic shock (Sepsis-3). JAMA. 2016;315(8):775–787. DOI 10.1001/jama.2016.0289. PMID 26903336.

3Screening & early recognition

Current approach (2026)
Guideline: NEWS/NEWS2/MEWS/SIRS over qSOFA (SSC 2026)Guideline: hospital PI program (SSC 2026)
Hospitals should run a sepsis performance-improvement program — systematic screening of acutely ill, high-risk patients, standard operating procedures for treatment, and quality-improvement tracking (a strong recommendation in 2026). For screening, use NEWS, NEWS2, MEWS, or SIRS in preference to qSOFA as a single tool. qSOFA is specific but too insensitive to be the lone screen; early, even prehospital, identification is encouraged.
Evidence — old → new
2016–21
qSOFA’s sensitivity problem. After Sepsis-3 promoted qSOFA, multiple validation cohorts found it highly specific but insensitive — many septic patients never meet 2 qSOFA points until late. Early-warning scores (NEWS/NEWS2/MEWS) and even SIRS detect deterioration earlier, which is what a screen needs.
2026
SSC 2026 (strengthened). Whereas 2021 advised against qSOFA as a single screening tool, 2026 issues a strong recommendation to use NEWS/NEWS2/MEWS/SIRS over qSOFA, and frames screening within a hospital-wide performance-improvement program (one of the guideline’s highest-certainty statements).

What changed. qSOFA moved from “promoted bedside screen” (2016) to “do not use alone” (2021) to “use NEWS/NEWS2/MEWS/SIRS instead” — a strong recommendation in 2026.

In practice

Wire an automated NEWS2 or MEWS alert into the EHR and triage. qSOFA ≥2 should still trigger escalation when seen, but never use it to rule out sepsis. Pair screening with a standard sepsis order set.

Sources (2)
  • Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Intensive Care Med / Crit Care Med. 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.
  • Singer M, et al (Sepsis-3, qSOFA derivation). JAMA. 2016;315(8):801–810. DOI 10.1001/jama.2016.0287. PMID 26903338.

4Antibiotics & source control

Current approach (2026)
Guideline: de-escalation — recommend (↑2026)Guideline: prolonged β-lactam infusion — recommend (↑2026)RCT: BLING-III neutral primary
Obtain blood cultures before antimicrobials (without materially delaying them), then give broad-spectrum IV antibiotics: within 1 hour for septic shock and for probable or definite sepsis without shock; for possible sepsis without shock, investigate rapidly and decide within 3 hours whether to start or defer antibiotics. Tailor empiric coverage to local epidemiology and patient risk — adding anaerobic or empiric MDR coverage only when specific risk factors are present (2026 suggests against it in low-risk patients). Achieve source control (drainage, debridement, device removal) as early as feasible. Give β-lactams as a prolonged (extended/continuous) infusion after a loading dose, and de-escalate once cultures and susceptibilities return — both now strong recommendations.
Evidence — old → new
timing
Why the 1 h / 3 h split. Retrospective cohorts in septic shock associate each hour of antibiotic delay with higher mortality, supporting ≤1 h there — and 2026 keeps ≤1 h for probable or definite sepsis even without shock. Only for possible (undifferentiated) sepsis without shock does 2026 allow a time-limited investigation with a decision to start or defer by 3 h — balancing speed against stewardship.
2024
BLING-III (β-lactam infusion). RCT, 7,202 patients with sepsis at 104 ICUs; continuous vs intermittent infusion of piperacillin-tazobactam or meropenem. 90-day mortality 24.9% vs 26.8% (favoring continuous but not statistically significant), with higher clinical cure. A companion meta-analysis tipped the guideline panel to upgrade to a strong recommendation for prolonged infusion after a loading dose.
de-esc.
De-escalation. Trials and large cohorts show narrowing therapy once susceptibilities are known is safe (no excess mortality) and reduces selective pressure for resistance — strong enough in 2026 to move from suggest to recommend.

What changed. Antibiotic timing was stratified by shock status (1 h vs 3 h); prolonged β-lactam infusion and de-escalation both rose from suggest to recommend, reflecting accumulated trial and stewardship evidence.

In practice

Draw cultures, give a loading dose, then run the β-lactam as an extended/continuous infusion (e.g. piperacillin-tazobactam, meropenem, cefepime) — a full (non-reduced) loading dose first, then adjust the maintenance rate for renal function / CRRT (consider therapeutic drug monitoring). Don’t wait on cultures if the patient is in shock. Reassess at 48–72 h and narrow to the narrowest effective agent.

Sources (2)
  • Surviving Sepsis Campaign 2026. Intensive Care Med / Crit Care Med. 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.
  • Dulhunty JM, et al (BLING III). Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis. JAMA. 2024;332(8):629–637. DOI 10.1001/jama.2024.9779. PMID 38864155.

5Fluid resuscitation

Current approach (2026)
Guideline: balanced > saline (↑2026)RCT: restrictive ≈ liberal (CLASSIC, CLOVERS)RCT: balanced ≈ saline (BaSICS, PLUS)
For sepsis-induced hypoperfusion or shock, begin with at least 30 mL/kg IV crystalloid in the first 3 hours, using balanced crystalloids in preference to 0.9% saline (upgraded in 2026). After that initial volume, if hypoperfusion persists, choose either a restrictive or a liberal strategy individualized to the patient and system (new in 2026 — the trials are neutral). Guide further fluids with dynamic measures (passive leg raise, pulse-pressure/stroke-volume variation, fluid-challenge response) rather than static pressures or exam alone, with POCUS as an adjunct. Avoid hydroxyethyl starch.
Evidence — old → new
2019
SMART — sepsis secondary analysis (balanced signal). A secondary analysis of the SMART trial’s sepsis subgroup (n=1,641) found balanced crystalloids lowered 30-day in-hospital mortality vs saline (26.3% vs 31.2%, adjusted OR 0.74, 95% CI 0.59–0.93) — the strongest single signal favoring balanced fluids.
2021–22
BaSICS & PLUS (no clear mortality difference). Two large blinded ICU RCTs — BaSICS (n=11,052) and PLUS (n≈5,000) — found no significant 90-day mortality difference between balanced solutions and saline overall. Meta-analyses still favor balanced slightly, underpinning the conditional 2026 preference.
2022
CLASSIC (restrictive ≈ standard). RCT, 1,554 patients with septic shock; restrictive vs standard IV fluids. 90-day mortality 42.3% vs 42.1% (adjusted difference 0.1 pt, 95% CI −4.7 to 4.9) — no difference.
2023
CLOVERS (restrictive/vasopressor-first ≈ liberal). RCT, 1,563 patients with sepsis-induced hypotension; early restrictive fluids with earlier vasopressors vs liberal fluids. No difference in 90-day mortality before discharge. Together with CLASSIC, this is why 2026 allows either strategy.

What changed. Balanced crystalloids became the preferred fluid; and the restrictive-vs-liberal question — “insufficient evidence” in 2021 — became an explicit “either strategy” after CLASSIC and CLOVERS came back neutral.

In practice

Give ~30 mL/kg balanced crystalloid (lactated Ringer’s / Plasma-Lyte) for hypotension or lactate ≥4, reassess with a dynamic measure (PLR, PPV) or POCUS, and stop bolusing when the patient is no longer fluid-responsive. After initial resuscitation, both a restrictive (earlier pressors) and a measured liberal approach are defensible.

Sources (4)
  • Surviving Sepsis Campaign 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.
  • Meyhoff TS, et al (CLASSIC). Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med. 2022;386(26):2459–2470. DOI 10.1056/NEJMoa2202707. PMID 35709019.
  • Zampieri FG, et al (BaSICS). Balanced solution vs 0.9% saline on mortality in critically ill patients. JAMA. 2021;326(9):818–829. DOI 10.1001/jama.2021.11684. PMID 34375394.
  • Brown RM, et al (SMART — sepsis secondary analysis). Balanced crystalloids versus saline in sepsis. Am J Respir Crit Care Med. 2019;200(12):1487–1495. DOI 10.1164/rccm.201903-0557OC. PMID 31454263.

6Vasopressors & hemodynamic targets

Current approach (2026)
Guideline: MAP ≥65 (SSC 2026)RCT: 65 vs higher MAP — no benefit (SEPSISPAM, 65)RCT: norepinephrine over dopamine (SOAP II)
Target an initial MAP ≥65 mmHg (strong); in older adults, a lower target may cut vasopressor exposure without harm. Norepinephrine is first-line — though 2026 downgraded this from “recommend” to “suggest” (over vasopressin or angiotensin II), acknowledging alternatives. Start vasopressors early — peripherally if needed — rather than waiting for central access. Add vasopressin as norepinephrine climbs, then epinephrine; angiotensin II is an option in refractory vasodilatory shock. For cardiac dysfunction with persistent hypoperfusion, add dobutamine or use epinephrine.
Evidence — old → new
2010
SOAP II — norepinephrine over dopamine. RCT, 1,679 patients in shock (mostly septic). No overall 28-day mortality difference, but dopamine caused more arrhythmia (24.1% vs 12.4%, P<0.001) and higher mortality in the cardiogenic-shock subgroup — establishing norepinephrine as the default.
2014
SEPSISPAM — no benefit from a higher MAP. RCT, 776 patients with septic shock; MAP 80–85 vs 65–70. No mortality difference at 28 or 90 days; the higher target caused more new atrial fibrillation (6.7% vs 2.8%). A chronic-hypertension subgroup needed less renal replacement at the higher target.
2008–16
Vasopressin (VASST, VANISH). VASST (n=778): adding vasopressin to norepinephrine did not reduce 28-day mortality overall (35.4% vs 39.3%, NS), with a possible benefit in less-severe shock. VANISH (n=409): early vasopressin vs norepinephrine gave no difference in kidney-failure-free days (less renal replacement therapy with vasopressin). Vasopressin remains a norepinephrine-sparing add-on, not a replacement.
2017
ATHOS-3 — angiotensin II. RCT in refractory vasodilatory shock; angiotensin II raised MAP markedly vs placebo (primary endpoint met) and reduced background catecholamine dose, leading to FDA approval. Not powered for mortality — reserved for refractory cases.
2020
65 trial — permissive hypotension in older adults. RCT, 2,463 patients ≥65 y with vasodilatory hypotension; MAP target 60–65 vs usual care. 90-day mortality 41% vs 44% — the primary unadjusted comparison was not significant (OR 0.89, 95% CI 0.76–1.04), reaching significance only after adjustment (OR 0.82, 95% CI 0.68–0.98), alongside less vasopressor exposure — supporting a lower target in patients ≥65 y.

What changed. Norepinephrine’s first-line status was downgraded to “suggest” (over vasopressin/angiotensin II); early peripheral initiation was endorsed; MAP ≥65 was reaffirmed, now with explicit room for a lower target in older adults.

In practice

Start norepinephrine without waiting for a central line — a peripheral line is fine short-term — and titrate to MAP ≥65 (consider 60–65 in patients ≥65 y). Add vasopressin ~0.03 U/min as norepinephrine rises, then epinephrine; keep angiotensin II for refractory shock and dobutamine for cardiac dysfunction.

Sources (7)
  • Surviving Sepsis Campaign 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.
  • De Backer D, et al (SOAP II). Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789. DOI 10.1056/NEJMoa0907118. PMID 20200382.
  • Asfar P, et al (SEPSISPAM). High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583–1593. DOI 10.1056/NEJMoa1312173. PMID 24635770.
  • Lamontagne F, et al (65 trial). Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension. JAMA. 2020;323(10):938–949. DOI 10.1001/jama.2020.0930. PMID 32049269.
  • Russell JA, et al (VASST). Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–887. DOI 10.1056/NEJMoa067373. PMID 18305265.
  • Gordon AC, et al (VANISH). Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. JAMA. 2016;316(5):509–518. DOI 10.1001/jama.2016.10485. PMID 27483065.
  • Khanna A, et al (ATHOS-3). Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–430. DOI 10.1056/NEJMoa1704154. PMID 28528561.

7Corticosteroids

Current approach (2026)
Guideline: suggest IV corticosteroids (SSC 2026)RCT: mortality benefit — APROCCHSSRCT: neutral mortality — ADRENAL
Give IV corticosteroids for septic shock — 2026 downgraded and broadened this by dropping the earlier “ongoing vasopressor requirement” qualifier (now a conditional suggest). Typically hydrocortisone 200 mg/day (50 mg IV every 6 h or a continuous infusion), with fludrocortisone 50 µg enterally daily a reasonable addition (the APROCCHSS regimen). In practice they are still used mainly in vasopressor-dependent shock, where they reliably speed shock reversal; the mortality effect is uncertain. Reserve for septic shock, not sepsis without shock.
Evidence — old → new
2018
ADRENAL (neutral on mortality). RCT, 3,800 patients with septic shock on vasopressors and ventilation; hydrocortisone 200 mg/day infusion vs placebo. No difference in 90-day mortality (27.9% vs 28.8%), but faster shock reversal, faster liberation from ventilation, and fewer transfusions.
2018
APROCCHSS (mortality benefit). RCT, 1,241 patients with septic shock; hydrocortisone + fludrocortisone vs placebo. 90-day mortality 43.0% vs 49.1% (P=0.03) — a survival benefit, in a sicker population and adding the mineralocorticoid fludrocortisone.

Why the trials differ. APROCCHSS enrolled sicker patients and added fludrocortisone; ADRENAL was larger with a continuous infusion. Both agree steroids reverse shock faster; they disagree on mortality — hence a conditional recommendation.

What changed. 2026 downgraded and broadened the recommendation — removing the “ongoing vasopressor requirement” qualifier so it now reads simply “suggest IV corticosteroids for septic shock.”

In practice

In vasopressor-dependent septic shock, start hydrocortisone 50 mg IV q6h (± fludrocortisone 50 µg enterally daily) — expect faster shock reversal. Monitor for hyperglycemia; taper as vasopressors come off.

Sources (3)
  • Surviving Sepsis Campaign 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.
  • Venkatesh B, et al (ADRENAL). Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808. DOI 10.1056/NEJMoa1705835. PMID 29347874.
  • Annane D, et al (APROCCHSS). Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–818. DOI 10.1056/NEJMoa1705716. PMID 29490185.

8Respiratory support & adjuncts to avoid

Current approach (2026)
Guideline: HFNC first (SSC 2026)Against: blood purification · probiotics · β-blockers (SSC 2026)
For sepsis-associated hypoxemic respiratory failure, use high-flow nasal cannula (HFNC) as the initial device (new in 2026), consider awake proning, and individualize oxygen targets. If mechanically ventilated without lung injury, a tidal volume of 6–8 mL/kg is acceptable. The guideline recommends against several low-value adjuncts: routine antipyretics to improve outcomes (symptom relief is fine), probiotics, β-blockers, and blood purification (hemoperfusion, high-dose hemofiltration, plasma exchange — the “against” was broadened from polymyxin B to all modalities).
Evidence — old → new
HFNC
High-flow nasal cannula first. In acute hypoxemic respiratory failure, HFNC reduces work of breathing and may lower intubation in selected patients; 2026 favors it as the first device for sepsis-related hypoxemia (a conditional, low-certainty recommendation), with awake proning as an adjunct.
adjuncts
Low-value adjuncts. Blood-purification devices have not improved mortality in RCTs; scheduled antipyretics do not change outcomes; probiotics and β-blockers lack benefit and carry risk. 2026 makes these explicit “against” statements to curb non-evidence-based use.

What changed. 2026 added HFNC-first and awake proning, permitted 6–8 mL/kg when there is no lung injury, and converted several adjuncts into explicit “against” recommendations — broadening the blood-purification “against” beyond polymyxin B.

In practice

Reach for HFNC before intubation in septic hypoxemia and prone awake, cooperative patients. Don’t deploy blood purification, probiotics, β-blockers, or scheduled antipyretics expecting an outcome benefit — treat fever for comfort, not for survival.

Sources (1)
  • Surviving Sepsis Campaign 2026. Intensive Care Med / Crit Care Med. 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.

9Post-sepsis care & transitions

Current approach (2026)
Guideline: post-discharge support & mental health (SSC 2026)
Plan recovery as deliberately as resuscitation. Screen survivors for new physical, cognitive, and mental-health impairment (post-sepsis / post-intensive-care syndrome). At transition, provide pharmacist-led medication reconciliation, structured post-discharge support and follow-up, advance care planning, and access to mental-health services. Involve patients and families throughout.
Evidence
survivors
The post-sepsis burden. Sepsis survivors face high readmission rates, new functional disability, cognitive decline, and depression/PTSD (post-intensive-care syndrome). Follow-up and rehabilitation programs improve some patient-centered outcomes; the 2026 guideline elevates transitions of care to an explicit pillar.

What changed. The “after the ICU” content expanded substantially in 2026 — advance care planning, medication reconciliation, post-discharge support, and mental-health access are now named recommendations rather than afterthoughts.

In practice

Build a discharge bundle: reconcile medications with a pharmacist, screen for PICS, arrange early follow-up and rehabilitation, connect survivors to mental-health support, and document goals of care.

Sources (1)
  • Surviving Sepsis Campaign 2026. Intensive Care Med / Crit Care Med. 2026. DOI 10.1007/s00134-026-08361-1. PMID 41869847.

10Where it’s heading (2026)

Precision sepsis. Sepsis is heterogeneous; biomarker- and transcriptomic-defined subphenotypes (including likely corticosteroid responders) are being tested to replace one-size-fits-all care.

Vasopressor sequencing. Trials of earlier vasopressin and earlier angiotensin II — and the optimal MAP in older adults (e.g. OVATION-65) — aim to refine the “norepinephrine-first” default that 2026 softened.

Fluids, both directions. After CLASSIC and CLOVERS neutralized the restrictive-vs-liberal debate, attention is shifting to de-resuscitation (active fluid removal) and POCUS-guided titration.

Diagnostics & stewardship. Rapid molecular pathogen tests and host-response assays promise faster targeted therapy and earlier de-escalation — central to the 2026 stewardship emphasis.

11Bottom line — the current sepsis bundle

  1. Recognize early — screen with NEWS/NEWS2/MEWS (not qSOFA alone); measure lactate.
  2. Blood cultures before antibiotics.
  3. Broad-spectrum antibiotics — ≤1 h in shock and in probable/definite sepsis; for possible sepsis, decide within 3 h; cultures first; loading dose then prolonged β-lactam infusion.
  4. At least 30 mL/kg balanced crystalloid for hypotension or lactate ≥4, then individualize with dynamic measures.
  5. Vasopressors for MAP ≥65 — norepinephrine first, started early/peripherally; add vasopressin, then epinephrine; angiotensin II if refractory (consider 60–65 in older adults).
  6. Hydrocortisone ± fludrocortisone in vasopressor-dependent shock.
  7. Source control as soon as feasible; de-escalate at 48–72 h.
  8. HFNC first for hypoxemia; lung-protective ventilation if intubated; avoid low-value adjuncts (blood purification, probiotics, β-blockers).
  9. Reassess perfusion (lactate clearance / capillary refill); avoid over-resuscitation.
  10. Plan recovery — medication reconciliation, follow-up, and mental-health support for survivors.

12FAQ

What is the difference between sepsis and septic shock?
Sepsis is life-threatening organ dysfunction (an acute SOFA rise of ≥2 points) caused by a dysregulated host response to infection. Septic shock is the subset with a vasopressor requirement to keep MAP ≥65 mmHg plus a serum lactate >2 mmol/L despite adequate fluid resuscitation — a group with substantially higher mortality (Sepsis-3).
How quickly should antibiotics be given in sepsis?
Within 1 hour for septic shock and for probable or definite sepsis even without shock; for possible (undifferentiated) sepsis without shock, investigate rapidly and decide within 3 hours whether to start or defer antibiotics (SSC 2026). Draw blood cultures first if it will not materially delay treatment.
How much fluid should be given in sepsis?
About 30 mL/kg of balanced crystalloid in the first 3 hours for hypoperfusion or shock, then individualize. After the initial resuscitation, both restrictive and liberal strategies are acceptable (CLASSIC and CLOVERS were neutral); guide further fluids with dynamic measures rather than static pressures.
What mean arterial pressure (MAP) should I target?
An initial MAP of at least 65 mmHg (SSC 2026). Targeting higher (80–85) added no benefit and caused more atrial fibrillation (SEPSISPAM). In older adults, a permissive 60–65 target reduces vasopressor exposure without increasing mortality (65 trial).
Which vasopressor is first-line for septic shock?
Norepinephrine — though 2026 phrases this as “suggest” rather than “recommend,” acknowledging vasopressin and angiotensin II as alternatives. Add vasopressin as the norepinephrine dose rises, then epinephrine; angiotensin II is an option in refractory vasodilatory shock. Start vasopressors early, peripherally if needed.
Are corticosteroids recommended in septic shock?
Yes, conditionally, for septic shock — 2026 dropped the earlier “ongoing vasopressor requirement” qualifier: hydrocortisone 200 mg/day (± fludrocortisone 50 µg enterally daily). In practice they are used mainly in vasopressor-dependent shock; steroids consistently speed shock reversal, with an uncertain mortality effect (positive in APROCCHSS, neutral in ADRENAL).
Is qSOFA still recommended to screen for sepsis?
No — 2026 recommends NEWS, NEWS2, MEWS, or SIRS over qSOFA as a single screening tool. qSOFA is specific but too insensitive to use alone; a qSOFA ≥2 should still prompt escalation when it occurs.

14Guidelines & evidence basis

Badges summarize each recommendation’s basis: Guideline: strong Guideline: conditional RCT benefit RCT neutral Against / harm. Guideline strengths use the GRADE classes quoted from the documents below.

Guidelines referenced (3)
  • Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Intensive Care Med. 2026 (simultaneously Crit Care Med.). DOI 10.1007/s00134-026-08361-1. PMID 41869847. — 129 statements (46 new); NEWS/NEWS2/MEWS/SIRS over qSOFA, MAP ≥65, prolonged β-lactam infusion and de-escalation upgraded to strong, norepinephrine first-line downgraded to conditional, balanced crystalloids preferred, either restrictive or liberal fluids after initial resuscitation.
  • Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. DOI 10.1001/jama.2016.0287. PMID 26903338. — current definitions: organ dysfunction (SOFA ≥2); septic shock = vasopressor + lactate >2 despite fluids; qSOFA.
  • Evans L, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47(11):1181–1247. DOI 10.1007/s00134-021-06506-y. PMID 34599691. — prior version superseded by SSC 2026; basis for the 1 h antibiotic, 30 mL/kg, and norepinephrine-first recommendations.

Disclaimer. This page is an educational summary of published evidence for clinicians and is not a substitute for individual clinical judgment or institutional protocols. Targets, doses, and thresholds are taken from the cited trials and guidelines; verify against current labeling, local guidelines, and patient-specific factors before applying. “In practice” notes are general practical guidance. Recommendation strengths are quoted from the cited guidelines (GRADE). Reviewed by the DosePilot Medical Team (Jun 2026); all citations verified against PubMed (PMID) and DOI on 2026-06-23.